Skip to main content
. Author manuscript; available in PMC: 2021 Jun 1.
Published in final edited form as: Surg Oncol. 2020 Feb 8;33:118–125. doi: 10.1016/j.suronc.2020.02.003

Fig. 1. Driver and actionable mutations:

Fig. 1.

Summary of all mutations identified using NGS in the 65 patients with PDA. From those 65 patients, actionable mutations with specific therapeutic options are identified in blue, with common PDA driver genes identified in yellow.